$OGI

4 Cannabis Stocks Log Momentum Gains Even As Congress Re-Criminalizes Some THC Products In Spending Bill - Organigram Global (NASDAQ:OGI), Cronos Group (NASDAQ:CRON)

Four cannabis stocks are demonstrating significant technical momentum, seemingly undeterred by new regulatory headwinds from Washington.

Original reporting
Benzinga · Rishabh Mishra
Published Nov 14, 2025, 12:33 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 14, 2025, 1:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
4 Cannabis Stocks Log Momentum Gains Even As Congress Re-Criminalizes Some THC Products In Spending Bill - Organigram Global (NASDAQ:OGI), Cronos Group (NASDAQ:CRON) — source image
Decision brief

The 30-second read

$OGIBullishMed
01

Why it matters

Despite these headwinds, technical momentum suggests trader optimism, possibly driven by sector resilience or speculative trading.

02

Market read

Sector exhibits resilience despite regulatory setbacks, with select stocks showing technical strength.

03

What to watch

Potential delays in regulatory decisions or broader market downturns could adversely affect these stocks.

Timing: Short-term (next 1-2 weeks)

Background

Recent legislative developments re-criminalizing certain THC products in the US have introduced regulatory headwinds for cannabis stocks.

Company-level read

Ticker impact

$OGIBullishMedium confidence
Context

High relevance due to positive sentiment and recent momentum.

Expected impact

Moderate upward movement in the next 1-2 weeks.

Evidence & confidence

Technical indicators suggest momentum; however, regulatory risks could temper gains.

$CRONBullishMedium confidence
Context

High relevance with somewhat bullish sentiment and recent momentum.

Expected impact

Potential modest increase over the next 1-2 weeks.

Evidence & confidence

Technical signals are favorable, but external headwinds may limit gains.

Market effects

Potential positive sentiment for the cannabis sector despite regulatory headwinds.

Limited regional impact; primarily US-based stocks affected.

Minimal global relevance; sector-specific news.

Counterpoint

Regulatory headwinds may intensify, leading to sharp declines in cannabis stocks, negating recent momentum.

Key entities

  • Congress

    US Congress re-criminalized some THC products in a recent spending bill.

  • Organigram Global

    Cannabis producer demonstrating momentum.

  • Cronos Group

    Cannabis company showing technical strength.

  • TLRY

    Cannabis company with neutral sentiment.

  • SNDL

    Cannabis company with limited momentum.

Related articles

$NVDAMedAI 8/10

Activist short seller Andrew Left convicted of securities fraud, sending shock waves through Wall Street

Activist short seller Andrew Left, founder of Citron Research, was convicted in Los Angeles federal court of securities fraud for allegedly manipulating stock prices using his social-media following. A jury found him guilty on 1 scheme count and 12 securities-fraud counts; prosecutors said he profited about $20 million. He plans to appeal and faces sentencing Aug. 31, with up to 25 years on the lead count.

$OGIMedAI 9/10

Organigram Global Inc (OGI) Raises 2026 Guidance on Sanity Acquisition

Organigram Global Inc (NASDAQ:OGI) reported March-quarter results on May 12. Net revenue fell 9% YoY to $59.8M and adjusted EBITDA was $0.9M versus $4.9M a year earlier, citing weakness in vapes, pre-roll production issues, and slower industry growth. The company raised 2026 revenue guidance to $350M from $300M, expecting Sanity Group (acquired end of March) to add about €25M quarterly revenue.

$BTDRMedAI 8/10

How Investors Are Reacting To Bitdeer Technologies Group (BTDR) Securing A 16-Year AI Data Center Deal

Bitdeer Technologies Group (BTDR) said its Tydal Data Center subsidiary in Norway signed a 16-year colocation lease and services deal with Volta Tydal AS for 121 MW and about $4.70 billion in contracted revenue, with an 8-year renewal option that could raise total value to about $8.0 billion. The campus is renewable-powered, set for NVIDIA GPU clusters, and includes $1.30 billion in credit support.

$CORZMed

Core Scientific (CORZ) Shareholders Rejected a $9B Sale. Does the AMD Deal Vindicate Them?

Core Scientific (CORZ) said it signed a 15-year infrastructure partnership with AMD (AMD) for data-center power starting in 2027. The deal covers about 530 MW across five sites, with AMD leasing 377 MW and a neocloud leasing 152 MW. Core Scientific said it has $14B+ potential base contracted revenue. The news follows shareholders rejecting a CoreWeave all-stock deal valued around $9B.